Latest Headlines

Latest Headlines

A behind-the-scenes look at Cards Against Biotechnology, Cubist's snarky 'last hurrah'

Earlier this year at the annual JP Morgan Healthcare conference--and about a month after the company announced that it would sell out to Merck for $8.4 billion--Cubist Pharmaceuticals started giving away decks of "Cards Against Biotechnology." A biotech-themed version of Cards Against Humanity, the game was a crowd-pleaser.

Merck and Zoetis line up rival vaccines to fight new strain of dog flu

After an outbreak of canine influenza sickened 1,000 dogs in the Chicago area, 5 of which died, some veterinarians were recommending vaccines made by Merck Animal Health and Zoetis. Problem was, those vaccines were designed to fight the H3N8 strain of the vaccine, which had been prevalent in the U.S. until this year. So vets couldn't promise those vaccines would do much to fight the new strain, H3N2.

Advera Health: Novartis, GSK asthma meds linked to more side effects than Merck drugs

Bestselling asthma drugs from Novartis and respiratory behemoth GlaxoSmithKline are also showing more adverse events in post-marketing safety data than competing products from Merck, according to a new report, potentially presenting issues further down the line as companies duke it out for market share.

Merck's third-place hep C combo posts quick cures in new study data

Merck, angling to compete with dominant hepatitis C treatments from Gilead Sciences and AbbVie, posted positive results for its in-development combos as it works to demonstrate their ability to cure more patients faster.

Merck to forge ahead with CETP-inhibiting cholesterol med

An independent data-monitoring panel recommended that Merck & Co. continue studying its cholesterol-fighting CETP inhibitor, anacetrapib. 

Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics of the antibiotic Cubicin, the drug that was key to its $9.5 billion buyout of Cubist. Next up may be an appeal to the U.S. Supreme Court.

Merck reiterates dedication to animal health with Harrisvaccines acquisition

Merck announced Nov. 12 that it will acquire Harrisvaccines, a private Iowa company that made news in October when the USDA appointed it to manufacture avian influenza vaccines for an emergency stockpile.

Merck's massive cardio study keeps rolling as fallen rivals pile up

Merck, the last Big Pharma standing in CETP inhibition, is pressing forward with a huge cardiovascular trial after getting the green light from its independent advisers, stepping over the scattered failures of similar projects in hopes of hitting upon a blockbuster.

EMA safety review raises no issues with HPV vaccines from Merck, GSK

For years, Merck and GlaxoSmithKline have battled safety worries and other stigmas with their HPV vaccines. But this week, the companies received a piece of positive news from the European Medicines Agency, which reported that a committee found no link between the shots and two rare conditions it had been studying.

Lilly, Merck and Valeant feel sting of DOJ drug pricing probe

Big Pharma has been dealing with government pushback over drug pricing. Now, Eli Lilly and Merck are joining Valeant in the hot seat as the U.S. Department of Justice probes the companies over how they report prices to government-funded drug programs.